Effective targeting of therapeutics to the CNS has been hampered by many biological obstacles, including the tight blood–brain barrier. In this Review, Srikanth and Kessler propose that the use of nanotechnology can overcome such issues. The authors discuss evidence for the efficacy of nanotechnology in CNS disorders, ranging from neurodegeneration to injury and brain tumours, and highlight the potential for the translation of nanotechnology-based therapeutics to the clinic.
- Maya Srikanth
- John A. Kessler
